Mereo BioPharma Group plc (NASDAQ:MREO) Holdings Lifted by NEOS Investment Management LLC

NEOS Investment Management LLC increased its position in shares of Mereo BioPharma Group plc (NASDAQ:MREOFree Report) by 751.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 351,905 shares of the company’s stock after acquiring an additional 310,577 shares during the period. NEOS Investment Management LLC owned approximately 0.28% of Mereo BioPharma Group worth $813,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Monaco Asset Management SAM increased its holdings in shares of Mereo BioPharma Group by 13.6% in the fourth quarter. Monaco Asset Management SAM now owns 676,494 shares of the company’s stock valued at $1,563,000 after buying an additional 80,765 shares in the last quarter. Golden State Equity Partners grew its holdings in shares of Mereo BioPharma Group by 41.0% in the 4th quarter. Golden State Equity Partners now owns 20,300 shares of the company’s stock worth $47,000 after acquiring an additional 5,900 shares during the last quarter. abrdn plc acquired a new stake in shares of Mereo BioPharma Group during the fourth quarter worth $3,583,000. Tejara Capital Ltd lifted its holdings in shares of Mereo BioPharma Group by 5.8% during the third quarter. Tejara Capital Ltd now owns 3,215,001 shares of the company’s stock valued at $4,147,000 after purchasing an additional 177,030 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its position in shares of Mereo BioPharma Group by 9.0% in the 3rd quarter. Rock Springs Capital Management LP now owns 7,676,481 shares of the company’s stock valued at $9,903,000 after purchasing an additional 634,090 shares during the period. 62.83% of the stock is currently owned by institutional investors.

Mereo BioPharma Group Price Performance

NASDAQ MREO traded down $0.07 during trading on Tuesday, reaching $3.38. The company’s stock had a trading volume of 500,235 shares, compared to its average volume of 1,394,803. The business has a 50-day moving average price of $3.06 and a 200-day moving average price of $2.99. Mereo BioPharma Group plc has a 1-year low of $1.00 and a 1-year high of $4.36.

Mereo BioPharma Group (NASDAQ:MREOGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.01) earnings per share for the quarter. As a group, equities analysts predict that Mereo BioPharma Group plc will post 0.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MREO has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Mereo BioPharma Group in a report on Thursday, May 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Thursday, May 16th.

Read Our Latest Stock Report on Mereo BioPharma Group

Insider Transactions at Mereo BioPharma Group

In other Mereo BioPharma Group news, insider Alexandra Hughes-Wilson sold 100,432 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $2.97, for a total transaction of $298,283.04. Following the completion of the transaction, the insider now owns 32,568 shares of the company’s stock, valued at approximately $96,726.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.13% of the stock is owned by corporate insiders.

Mereo BioPharma Group Company Profile

(Free Report)

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

Read More

Institutional Ownership by Quarter for Mereo BioPharma Group (NASDAQ:MREO)

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.